Kornimate/medical-research-clean huggingface dataset:
inhaled essential oil effect on common qol concerns during cancer treatment

Conditions: Gastrointestinal Cancer; Neuroendocrine Carcinoma; Skin Cancer

Summary: this single-blind, randomized controlled trial studies how well inhaled essential oils work for common quality of life concerns in patients who are undergoing cancer treatment such as chemotherapy, targeted therapy, and/or immunotherapy given through the vein (intravenously). aromatherapy using essential oils, such as ginger essential oil, german chamomile essential oil, and bergamot essential oil, may improve quality of life issues such as nausea, anxiety, loss of appetite, and fatigue in patients undergoing treatment for cancer.

primary objectives: i. to determine if aromatherapy, specifically inhaled essential oil, is beneficial for side effects related to cancer treatments involving chemotherapy, targeted therapy, and/or immunotherapy administered intravenously. ii. to describe the effect of inhaled ginger essential oil, german chamomile essential oil, and bergamot essential oil on nausea and anxiety of patients receiving chemotherapy, targeted therapy, and/or immunotherapy administered intravenously. iii. to describe the effect of decreased levels of nausea and/or anxiety on levels of appetite and/or fatigue. iv. to evaluate the acceptability of using a personal inhalation bottle for inhalation of essential oils. outline: patients are randomized to 1 of 4 groups. group i: patients inhale 7 drops of bergamot essential oil using a personalized inhalation bottle three times daily (tid) (morning, midday, and evening) for up to 7 days. patients also use a journal to document symptoms, time of inhalation, and medication use tid for up to 7 days. group ii: patients inhale 7 drops of chamomile essential oil and complete journal as in group i. group iii: patients inhale 7 drops of ginger essential oil and complete journal as in group i. group iv (control): patients inhale 7 drops of almond essential oil and complete journal as in group i.

Eligibility criteria:
inclusion criteria: * gastrointestinal cancers, neuroendocrine cancer, or melanoma or other skin cancers * receiving chemotherapy, targeted therapy, and/or immunotherapy * not naive to the treatment * must be able to read and write english exclusion criteria: * allergies to ragweed, chrysanthemum, chamomile, ginger, bergamot, citrus fruits, tree nuts, perfumes * asthma diagnosis * patients receiving only octreotide injections * patients receiving floxuridine (fudr) via hepatic artery infusion (hai) pump only

Keywords: aromatherapy essential oils gastrointestinal cancer neuroendocrine cancer melanoma skin cancer
i-prf after arthrocentesis plus botox injection to lateral pterygoid muscle in treatment of anterior disc displacement

Conditions: TMJ Disc Disorder; TMJ Pain

Summary: aim of study : to evaluate the efficacy of tmj arhtrocentesis followed by injection of liquid platelet rich fibrin (i-prf ) in addition to intramuscular injection of lateral pterygoid muscle with botulinum toxin on clinical outcomes of painful tmj , maximum mouth opening , joint sounds and range of lateral movement in patients with tmj anterior disc displacement with reduction hypothesis : intramuscular injection of lateral pterygoid muscle with botulinum toxin plus tmj intra-articular injection of liquid platelet rich fibrin after arthrocentesis are more effective than tmj arthrocentesis followed by intra-articular injection of ( i-prf ) or tmj arthrocentesis only .


Eligibility criteria:
inclusion criteria: * patients with painful tmj during jaw movements * patients with joint sounds ( clicking ) during jaw opening and mastication * patients age range from 16 years old to 45 years old * patients with class i maxillo-mandibular relationship * patients with reduced mouth opening * all patients diagnosed clinically and radiographically by mri as tmj anterior disc displacement with reduction exclusion criteria: * patient with history of recent trauma * patients with malocclusion * patients with systematic condition that affect bone and joints such as osteoarthritis , systemic lupus and epilepsy . * patients allergic to botox injection * pregnant or lactating females * patients with non-reducible disc on mri * patients contraindicated to exposure to mri * patients with previous tmj arthrocentesis , arthroscopy or tmj surgery * significant mechanical obstruction that prevents mouth opening, acute capsulitis, benign or malignant temporomandibular joint lesions. * patients with blood diseases, and coagulation disorders

Keywords: anterior disc displacement tmj clicking i-prf lateral pterygoid muscle arthrocentesis botulinum toxin type a
effect of liraglutide on heart frequency in healthy volunteers

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in the united states of america (usa). the aim of this trial is to investigate if liraglutide effects the qtc interval. moxifloxacin (avelox®) is administered as positive control.


Eligibility criteria:
inclusion criteria: * healthy * fasting plasma glucose within normal limits (80-100 mg/dl) * bmi (body mass index): 20.0-29.0 kg/m\^2 (inclusive) * heart rate within the range of 50-90 beats per minute (inclusive) * subject is judged to be in good health on the basis of their medical history, physical examination, ecg (electrocardiogram), and routine laboratory data exclusion criteria: * any clinically significant disease history, in the opinion of the investigator, of systemic or organ disease * any clinically significant disease history, in the opinion of the investigator, of cardiovascular disease * clinically significant abnormalities on any pre-study clinical examination or any abnormal laboratory measurements during screening * a family history of sudden cardiac death at age less than 50 years old * t-wave abnormalities * individual or familial history of long qt syndrome * positive results on screening for hepatitis b surface antigen, hepatitis c antibody or hiv (human immunodeficiency virus) antibody * positive results on the urine drug and alcohol screen * any regular use of prescription or nonprescription drugs or vitamins and herbal/nutritional supplements that cannot be stopped at screening * any strenuous exercise (as judged by the investigator) from 4 days prior to randomisation and during the entire trial period * blood donation, trauma or surgery with blood loss exceeding 500 ml within the last 2 months prior to dosing * subject is a smoker, occasional smoker or has a history of smoking (or use of any tobacco) within the last 3 months * excessive use of methylxanthine-containing beverages (more than 8 cups/day of coffee, tea, soda or chocolate) * females who are pregnant, breastfeeding, intend to become pregnant within the next 3 months, or who are judged to be using inadequate contraceptive measures * a history (within the last 2 years) of drug or alcohol abuse
intermittent oro-esophageal tube feeding on dysphagia in stroke survivor

Conditions: Stroke

Summary: this was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. all patients were given comprehensive rehabilitation therapy. during the treatment, enteral nutrition support was provided for the two groups by intermittent oro-esophageal tube feeding and nasogastric tube feeding, respectively. nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

dysphagia in patients after stroke continues to be a challenge. to avoid the wound caused by gastrostomy, nasogastric tube feeding has been the mainstay of palliation, but potential side effects exist this choice. intermittent oro-esophageal tube feeding is an established modality that can be used with comprehensive rehabilitation therapy. this study reports the outcomes of intermittent oro-esophageal tube feeding and comparison with nasogastric tube feeding, including nutritional status, dysphagia, quality of life, depression, and follow-up in patients receiving comprehensive rehabilitation therapy.this was a prospective multicenter study. the patients after stroke with were randomly divided into the observation group and the control group. all patients were given comprehensive rehabilitation therapy. during the treatment, enteral nutrition support was provided for the two groups by intermittent oro-esophageal tube feeding and nasogastric tube feeding, respectively. nutritional status, dysphagia, quality of life and depression before and after treatment were compared.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * meeting the diagnostic criteria of stroke; * any degree of dysphagia at admission; * steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. * transferred out within three weeks of hospitalization in the neurology department. exclusion criteria: * complicated with other neurological diseases; * damaged mucosa or incomplete structure in nasopharynx; * tracheostomy tube plugged; * unfeasible to the support of parenteral nutrition; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
balneotherapy and anxiety during sars-cov-2 pandemic

Conditions: D001452

Summary: investigators will measure the level of anxiety and fear of covid during the balneological treatment in patients. they are interested in the effect of general trust and resilience on the level of anxiety state.

investigators will measure the level of anxiety and fear of sars-cov-2 virus during the balneological treatment in patients. they are interested in the effect of general trust and resilience on the level of anxiety state. a number of between 300 and 800 inpatients are expected to get involved in the study. they suffer from cardiovascular disease, osteoarthritis, respiratory diseases and many others.

Eligibility criteria:
inclusion criteria: * enrolled in balneological treatment exclusion criteria: * not enrolled in the balneological treatment

Keywords: balneology anxiety fear of sars-cov-2 resilience general trust
a post marketing observational study of activities of daily living in advanced parkinson's disease patients with early troublesome motor fluctuations and treated with duodopa - a multi-country study

Conditions: Parkinson's Disease

Summary: patients with advanced parkinson's disease experience a range in the severity of their motor fluctuations. the rationale for this post marketing observational study is to demonstrate the benefits of duodopa treatment on parkinson's disease patients entering the advanced stage of the disease whose motor fluctuations have become troublesome and complicate management with oral therapy. the aim of this post-marketing observational study is to assess the effect of duodopa treatment on activities of daily living in advanced parkinson's disease participants characterised by either 2-4 hours of "off" time or 2 hours of non-troublesome or troublesome dyskinesia daily, supported by a unified parkinson's disease rating scale total score in the best "on" state of at least 40 points at baseline.

data are recorded from visits most closely aligned with the planned periods of visit 0 (v0): baseline (after decision to use the temporary naso-duodenal tube (approximately 2-14 days) and after signature of the patient authorization/informed consent form); visit 1 (v1): at discharge from hospital; visit 2 (v2): 3 months after discharge; visit 3 (v3): 6 months after discharge; visit 4 (v4): 12 months after discharge. all participants have a temporary naso-duodenal tube used initially with the infusion pump to determine if the participant responds favorably to this method of treatment and to optimize the dose of duodopa before permanent treatment is started. participants who choose a treatment other than duodopa after the temporary naso-duodenal test phase are considered for the standard of care group. participants who go on to select apomorphine pump or deep brain stimulation at any stage are not eligible to continue in this group or to continue in the observational period of study. participants who continue to with duodopa treatment after the the temporary naso-duodenal test phase are the duodopa group.

Eligibility criteria:
inclusion criteria: * has advanced levodopa-responsive parkinson's disease * the decision to treat with duodopa is made by the physician in accordance with the local label (summary of product characteristics; product label) prior to any decision to approach the patient to participate in this study * parkinson's disease (pd) medicinal treatment is unchanged for at least four weeks prior to baseline * takes oral medication four or more times daily * either has 2-4 hours of "off" time or 2 hours of non-troublesome or troublesome dyskinesia daily supported by a unified parkinson's disease rating scale (updrs) total score in the best "on" state of at least 40 points at baseline; based on documented medical history exclusion criteria: * use of deep brain stimulation (dbs), apomorphine pump or duodopa treatment prior to baseline visit * severe dementia based on a mini-mental state examination (mmse) of \< 24

Keywords: early observational advanced parkinson's disease
thyroid function in late preterm infants

Conditions: Transient Hypothyroxinemia

Summary: transient hypothyroxinemia (th) is a condition characterized by low levels of serum thyroxine (t4) and normal levels of thyroid stimulating hormone (tsh). th in premature infants has been found to be related to severity of illness. t4 levels in very low birth weight infants born prematurely has been found to be inversely correlated to severity of illness. in very low birth weight infants, th has been associated with poor outcomes. little is known about thyroid function in late preterm infants. hypotheses: 1. ill late preterm infants will have lower total t4 levels than healthy late preterm infants. 2. total t4 and possibly tsh levels will be inversely correlated with short-term outcomes. 3. late preterm infants born by cesarean section will have lower t4 levels compared to those born by vaginal birth.


Eligibility criteria:
inclusion criteria: * any infant born between 34 0/7 weeks and 36 6/7 weeks gestation born at christiana hospital exclusion criteria: * outborn infants * infants with major congenital anomalies

Keywords: transient hypothyroxinemia late preterm infants total t4 tsh illness severity nicu
diabetes mellitus after intensive care admission

Conditions: Stress Hyperglycemia; Diabetes Mellitus

Summary: stress hyperglycaemia is commonly observed during hospitalization in the intensive care unit (icu) and has been shown to adversely influence outcome. it has been hypothesized that, when it occurs in previously non-diabetic patients, it reflects a latent disturbance of the glucose metabolism. assessing the incidence of this phenomenon and identifying its risk factors could support prevention, detection and early treatment of impending diabetes mellitus type 2. we will perform a glucose tolerance test approximately 6-9 months post-icu admission to screen for disorders of glucose metabolism. furthermore, we examined characteristics that could have predicted the post-discharge disturbances: patient characteristics, parameters of disease severity and of glucose metabolism, as well as the findrisc (finnish diabetes risc score). we plan to enroll 400 patients.


Eligibility criteria:
inclusion criteria: * ≥ 18 years old) * admitted for 36 hours or longer to the icu * still alive 6 months after icu discharge exclusion criteria: * known diabetes mellitus or any other glucose tolerance disturbance * an estimated short life expectancy * pregnancy * a history of transplantation or acute pancreatic disease * language barrier preventing a clear understanding of the informed consent
prevention of severe acute graft-versus-host disease in adult patients using a dagoat model

Conditions: Transplant-Related Disorder

Summary: to evaluate the efficacy and safety of ruxolitinib for prophylactic therapy of adult patients who are predicted to have a high risk for developing severe acute graftversus-host disease (agvhd) by the dynamic agvhd onset anticipation tianjin (dagoat) model.

this study aims to prospectively evaluate the use of the dagoat model in real-world clinical settings at the institute of hematology, chinese academy of medical sciences (ihcams).

Eligibility criteria:
inclusion criteria: 1. patients must be \> 16 years of age; 2. patients receiving human leukocyte antigen mismatched and non-cord blood allogeneic hematopoietic stem cell transplantation; 3. patients who can take oral medication; 4. patients have to sign an informed consent form before the start of the research procedure. exclusion criteria: 1. tandem transplantation or multiple transplantations; 2. patients who are allergic to or cannot tolerate ruxolitinib ; 3. mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements ; 4. patients who are pregnant or cannot take appropriate contraceptive measures during treatment; 5. patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.
stim+: pet biomarker education & disclosure

Conditions: Mild Cognitive Impairment; Dementia; Alzheimer's Type (Etiology)

Summary: when dementia is caused by ad, we refer to it as dementia of the alzheimer's type (dat). the greatest risk factor for alzheimer's disease (ad) and dat is advancing age, but dat is not a normal part of aging. studies have shown that changes in the brain happen before full symptoms of dat develop. these changes include a buildup of two proteins within the brain, called amyloid and tau. the two goals of this study are (1) to determine whether patients with mild cognitive impairment or dementia-alzheimer's type (dat) are able to demonstrate decisional capacity to engage in pet amyloid and tau disclosure after receiving education; and (2) to assess how patients and care partners react to pet amyloid and tau biomarker disclosure.


Eligibility criteria:
inclusion criteria: * enrolled in the stimulation to improve memory study (nct03875326). * completed pet scan with amyloid and/or tau tracer success. * demonstrates decision-making capacity to engage in pet disclosure, or has a care partner in attendance that demonstrates decision-making capacity for the participant to engage in disclosure * if diagnosed with dat: must have a cognitively intact study partner (i.e., their care partner) * if diagnosed with mci: strongly recommended to have a cognitively intact study partner (i.e., their care partner) exclusion criteria: * active diagnosis of moderate depression or anxiety without treatment * newly diagnosed neurologic disease (since completion of stimulation to improve memory study activities)
dose finding study for remimazolam in children

Conditions: Drug Effect

Summary: this study aims to find effective dose of remimazolam for inducing loss of consciousness in children aged 2 to 8 years old. we will explore ed90 of remimazolam for loss of consciousness in 2 minutes after intravenous injection, via a up-and-down method with biased-coin design.

we will administer remimazolam intravenously to the study participants. remimazolam will be infused in 30 seconds to the participants, and we will wait for 2 minutes for the participants be sedated. when a participant was not sedated in 2 minutes, dose of remimazolam in the next participant will be escalated by 0.05mg/kg. when a participant was sedated in 2 minutes, dose of remimazolam in the next participant will be decreased by 0.05mg/kg or maintained as same. the probability of decrement and maintenance will be 90% and 10% respectively. the dose of remimazolam in the first participant of the study will be 0.05mg/kg. we will collect the results and obtain ed90 of remimazolam for loss of consciousness in children aged 2 to 8 years old.

Eligibility criteria:
inclusion criteria: * children scheduled to undergo general anesthesia or sedation * american society of anesthesiologist physical status of 1 or 2 exclusion criteria: * presence of upper respiratory tract infection or any pulmonary disease * presence of subglottic stenosis, laryngomalacia, or tracheomalacia * history of hypersensitivity to benzodiazepines or propofol * history of hypersensitivity to beans or peanut * history of seizure * presence of arrhythmia, tachycardia, or bradycardia * presence of acute closed-angle glaucoma * patients with unstable vital sign * presence of sleep apnea * presence of galactose intolerance, lapp lactase deficiency, or glucose-galactose absorption disorder * history of hypersensitivity to dextran 40 * refusal to enroll by one or more parents or legal guardian * other conditions the researchers regarded as inappropriate to enroll

Keywords: remimazolam children dose
evaluation of amniotic fluid product in knee osteoarthritis

Conditions: Osteoarthritis of the Knee

Summary: a study evaluating amniotic fluid compared to a saline placebo injection in the treatment of subjects with osteoarthritic (oa) knee pain


Eligibility criteria:
inclusion criteria: 1. subject is 30 years or older. 2. subject has a diagnosis of osteoarthritis (oa) defined as grade 1 to 3 on the kellgren lawrence grading scale. 3. subject is willing and able provide informed consent and participate in all procedures and follow-up evaluations necessary to complete the study. exclusion criteria: 1. subject has active infection at the injection site. 2. subject has rheumatoid arthritis, psoriatic arthritis, or have been diagnosed with any other auto-immune disorders that could be the cause of their knee pain. 3. bmi greater than 45 kg/m2 4. subject has received an intra-articular hyaluronic acid (ha) injection for the treatment of oa of the target knee within 3 months prior to screening. 5. subject has received a steroid or platelet rich plasma (prp) injection for the treatment of oa of the target knee within 3 months prior to screening. 6. subject has had major surgery, arthroplasty or arthroscopy in the target knee within 26 weeks of treatment or plans to have surgery in the target knee within 180 days of treatment. 7. subject is pregnant or plans to become pregnant within 180 days of treatment. 8. subject has used an investigational drug, device or biologic within 12 weeks prior to treatment. 9. subject has any significant medical condition that, in the opinion of the investigator, would interfere with protocol evaluation and participation. 10. subject has a history of immunosuppressive or chemotherapy in the last 5 years 11. subject has autoimmune disease or a known history of having acquired immunodeficiency syndrome (aids) or hiv 12. subject has had prior radiation at the site 13. subject is currently taking anticoagulant therapy (excluding plavix or aspirin) 14. diagnosis of gout in the past 6 month 15. subject has a diagnosis of osteoarthritis

Keywords: oa, osteoarthritis, knee